Clinigen, Inc.
Quick facts
Marketed products
- High Dose Interleukin-2
- vemurafenib + HD IL-2 · Oncology
Vemurafenib inhibits mutant BRAF kinase to block tumor cell proliferation, while high-dose IL-2 activates the immune system to enhance anti-tumor immunity.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: